title: [Experience at a branch center of the National HIV Protease Inhibitor Registry].
abstract: In the present study we show our experience as one of the Centers (center 006) of the Italian Index of Protease Inhibitors (PI). In this multicentric, observational study we studied HIV-positive naive patients for antiretroviral therapy with protease inhibitors. From 8/1/97 to 31/1/98 in our department 64 patients were enrolled and followed up through an electronic medical sheet in order to evaluate efficacy, tolerability, toxicity and compliance of treatment with PI. Our results show a reduction in AIDS-related mortality and a decrease in AIDS defining diseases: in particular data show an increase in CNS pathologies in comparison with other opportunistic events. Moreover, in patients non complaints to therapy, the progression of the disease was more frequent. The side effects more frequently observed during PI treatment were hypertrigliceridaemia and lipodystrophy; gynaecomastia and hyperprolactinaemia were even present, perhaps as expression of direct metabolic action of HAART therapy.
authors.affiliation: VIII Divisione di Malattie Infettive, Azienda Ospedaliera "Domenico Cotugno", Napoli, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Franco
authors.forename: L
authors.initials: L
authors.lastname: Aprea
authors.forename: A
authors.initials: A
authors.lastname: Geraci
authors.forename: E
authors.initials: E
authors.lastname: Manzillo
authors.forename: T
authors.initials: T
authors.lastname: Pizzella
authors.forename: F
authors.initials: F
authors.lastname: Simioli
authors.forename: A
authors.initials: A
authors.lastname: Mongirulli
authors.forename: C M
authors.initials: CM
authors.lastname: Izzo
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000453:epidemiology; D000328:Adult; D000368:Aged; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D018791:CD4 Lymphocyte Count; D002493:Central Nervous System Diseases / Q000453:epidemiology; D003625:Data Collection; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D004363:Drug Utilization / Q000706:statistics & numerical data; D005260:Female; D005500:Follow-Up Studies; D006177:Gynecomastia / Q000139:chemically induced; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D006966:Hyperprolactinemia / Q000139:chemically induced; D015228:Hypertriglyceridemia / Q000139:chemically induced; D007558:Italy; D008060:Lipodystrophy / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D010292:Paresthesia / Q000139:chemically induced; D010349:Patient Compliance; D012367:RNA, Viral / Q000097:blood; D012042:Registries / Q000706:statistics & numerical data*; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D012367:RNA, Viral